Cystic Fibrosis Therapy Area Overview 2021: Notable Companies Include Abbvie, Chiesi, Sanofi, ReCode Therapeutics and Viatris
January 13, 2022 06:43 ET
|
Research and Markets
Dublin, Jan. 13, 2022 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis (CF) Therapy Area Report" report has been added to ResearchAndMarkets.com's offering. Companies Mentioned ...
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis
January 06, 2022 16:05 ET
|
ContraFect Corporation
YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Aceragen Announces $3.5 Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations
January 06, 2022 09:00 ET
|
Aceragen
Raleigh-Durhan, NC, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for orphan diseases with high unmet medical need, today...
Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for Development of ACG-701 as Medical Countermeasure Against Melioidosis
January 05, 2022 09:00 ET
|
Aceragen
Raleigh-Durham, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Arrevus, Inc., a clinical-stage biopharmaceutical company developing therapies for orphan infectious diseases with high unmet medical need, ...
EnBiotix, Inc. Closes $11M Pre-Merger Financing
December 29, 2021 02:30 ET
|
EnBiotix, Inc.
BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M pre-merger, convertible...
ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis
November 09, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Aceragen Announces Acquisition of Arrevus, Expands Late-Stage Rare Disease Pipeline
November 01, 2021 10:13 ET
|
Aceragen
RALEIGH-DURHAM, N.C , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and orphan diseases, today announced...
ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients
October 26, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Designer Harris Reed Donates Jewelry to Claire’s Place Foundation Auction
October 13, 2021 09:00 ET
|
Claire's Place Foundation
Los Angeles, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is proud to...
First Wave BioPharma Announces Two Additions to Scientific Advisory Board
October 12, 2021 08:30 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...